Professor Peter Scanlon

Senior Research Fellow

Prof. Peter Scanlon has been Clinical Director for the English NHS Diabetic Eye Screening Programme since 2003, and he has, with the support and co-operation of colleagues, moved screening from limited ad hoc delivery of services to systematic quality assured processes for screening, assessment and treatment across all of England to 2.9 million people with diabetes. He is an Associate Professor of the University of Oxford. Prof. Scanlon is also a Visiting Professor at the University of Gloucestershire. Dr Scanlon is Lead Author of the textbook ‘Practical Manual of Diabetic Retinopathy Management’ and has written the Diabetic Retinopathy Chapter for the Textbook of Diabetes, 4th Edition (both Wiley Blackwell).


Prof. Scanlon provides tutorials for the medical students in ophthalmology and laboratory based medicine


His research interests lie in the Screening, Epidemiology, Assessment and Treatment of Diabetic Retinopathy and he has published extensively in these areas.

Recent Publications

Oke JL, Stratton IM, Aldington SJ, Stevens RJ, Scanlon PH. The use of statistical methodology to determine the accuracy of grading within a diabetic retinopathy screening programme. Diabet Med. 2015 Dec 15. PubMed PMID: 26666463

Scanlon PH, Loftus J, Starita C, Stratton IM, The use of weighted health-related Quality of Life scores in people with diabetic macular oedema at baseline in a randomized clinical trial.  (2015), Diabet Med, 32, 97 – 101

Scanlon PH, Aldington SJ, Leal J, et al. Development of a cost-effectiveness model for optimisation of the screening interval in diabetic retinopathy screening. Health Technol Assess 2015;19:1-116.

Scanlon PH, Stratton IM, Leese GP, et al. Screening attendance, age group and diabetic retinopathy level at first screen. Diabet Med 2015. Diabet Med. 2015 Sep 4. doi: 10.1111/dme.12957. . [Epub ahead of print]

Leese GP, Stratton IM, Land M, et al. Progression of Diabetes Retinal Status Within Community Screening Programs and Potential Implications for Screening Intervals. Diabetes Care 2015;38 488-94

Scanlon PH, Dirani M, van Wijngaarden P. Screening for sight‑threatening diabetic retinopathy: An update. Egyptian Retina Journal 2014;2(1):3-18.

Hipwell A, Sturt JA, Lindenmeyer A, Stratton IM, Gadsby R, O’Hare P, Scanlon PH. Attitudes, access and anguish: a qualitative interview study of staff and patients’ experiences of diabetic retinopathy screening. BMJ Open2014;4:e005498 doi:10.1136/bmjopen-2014-005498

Scanlon P.H. Aldington S.J. Stratton I.M. (2014) Delay in Diabetic Retinopathy Screening Increases the Rate of Detection of Referable Diabetic Retinopathy. Diabet Med 31(4): 439-442.

Lindenmeyer A, Sturt JA, Hipwell A, Stratton IM, Al-Athamneh N, Gadsby R, O’Hare JP, Scanlon PH, Influence of primary care practices on patients’ uptake of diabetic retinopathy screening: a qualitative case study. (2014), Br J Gen Pract, 64, e484 – e492

Simó R, Hernández C; on behalf of the European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)*. Neurodegeneration in the diabetic eye: new insights and therapeutic perspectives”(Trends Endocrinol Metab 2014;25:23-33)

Healy R, Sallam A, Jones V, et al. Agreement between photographic screening and hospital biomicroscopy grading of diabetic retinopathy and maculopathy.  (2014), Eur J Ophthalmol, 24, 550 – 558

For a complete list of publications, see Dr Scanlon’s Faculty webpage.